Search

Search Constraints

You searched for: Author/Creator Helmer, Eric

Search Results

1. A Dual‐Administration Microtracer Technique to Characterize the Absorption, Distribution, Metabolism, and Excretion of [14C]Seletalisib (UCB5857) in Healthy Subjects. (26th June 2017)

2. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome. (19th September 2020)

3. AB0458 A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY OF ORAL SELETALISIB IN PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME (PSS). (June 2019)

5. Evaluating Placental Transfer of Certolizumab Pegol and Polyethylene Glycol During Pregnancy: Results From CRIB, a Prospective, Post‐Marketing, Multicenter, Pharmacokinetic Study: 641. (October 2017)

6. First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis. (10th January 2017)

8. Lack of placental transfer of certolizumab pegol during pregnancy: Results from CRIB, a prospective, postmarketing, multicenter, pharmacokinetic study. (March 2019)

9. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Issue 2 (13th October 2017)

10. Pharmacokinetics and Metabolism of Ziritaxestat (GLPG1690) in Healthy Male Volunteers Following Intravenous and Oral Administration. Issue 2 (11th October 2021)